Clark, Gary M.

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science

HER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

Cited by 11,760

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 5,419

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 3,848

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)

McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute

Meta-analysis and systematic reviewsStatistical Methods in Epidemiology

Cited by 2,162

REporting recommendations for tumour MARKer prognostic studies (REMARK).

for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · British Journal of Cancer

Meta-analysis and systematic reviewsStatistical Methods in Epidemiology

Cited by 1,394

Time-dependence of hazard ratios for prognostic factors in primary breast cancer

Hilsenbeck, S. G., Ravdin, P. M., de Moor, C. A., Chamness, G. C., Osborne, C. K., & Clark, G. M. (1998) · Breast Cancer Research and Treatment

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 237

Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion

Kuhn, J. G., Von Hoff, D. D., Hersh, M., Melink, T., Clark, G. M., Weiss, G. R., & Coltman, C. A. (1989) · European Journal of Cancer and Clinical Oncology

Cancer therapeutics and mechanismsBioactive Compounds and Antitumor Agents

Cited by 14